BriaCell Therapeutics (BCT) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing novel immunotherapies for cancer, with lead programs in metastatic breast cancer and preclinical assets in prostate cancer and other indications.

• Lead candidate Bria-IMT™ is in a pivotal Phase 3 trial for metastatic breast cancer, with FDA Fast Track designation; additional programs include Bria-OTS™, a personalized off-the-shelf immunotherapy, and Bria-PROS+™ for prostate cancer.

• Recent clinical data show promising efficacy in heavily pretreated and antibody-drug conjugate (ADC) resistant breast cancer patients, including those with CNS metastases.

• The company is also advancing next-generation immunotherapy platforms and has entered into clinical supply agreements with partners such as BeiGene.

Financial performance and metrics

• For the nine months ended April 30, 2025, operating loss was $18.7 million, with total operating expenses of $22.8 million.

• As of April 30, 2025, cash and cash equivalents were $12.5 million, with total assets of $17.0 million and shareholders' equity of $11.9 million.

• Net loss per share for the nine months ended April 30, 2025 was $(6.70), with a weighted average of 2,717,927 shares outstanding.

Use of proceeds and capital allocation

• Estimated net proceeds from the offering are approximately $18.04 million, assuming all securities are sold at the assumed price and no warrants are exercised.

• Proceeds are intended for working capital, general corporate purposes, and advancement of business objectives, with management retaining broad discretion over allocation.